Details of Drug

Drug General Information (ID: D1381)
Drug Name	Ranitidine
Drug Type	Small molecule
Drug Synonymous	Achedos; Acidex; Alquen; Atural; Axoban; Biotidin; Coralen; Curan; Duractin; Ezopta; Fendibina; Gastrial; Gastridina; Gastrolav; Gastrosedol; Istomar; Kuracid; Logast; Mauran; Melfax; Microtid; Noctone; Ptinolin; Quantor; Quicran; RND; Radinat; Randin; Raniben; Raniberl; Ranibloc; Ranidine; Ranifur; Ranin; Raniogas; Raniplex; Ranisen; Raniter; Ranitidin; Ranitidina; Ranitidinum; Ranitiget; Ranitin; Rantacid; Rantidine; Ratic; Raticina; Sampep; Sostril; Taural; Terposen; Ulceranin; Ulcex; Ultidine; Urantac; Verlost; Vesyca; Vizerul; Weichilin; Weidos; Xanidine; ZANTAC; Zantab; Zantadin; Zantic; Ranitidine HCL; Rantidine HCL; Nu-Ranit; Rani-Q; Rani-nerton; Ranitidina [INN-Spanish]; Ranitidine (TN); Ranitidinum [INN-Latin]; Ul-Pep; Zantac (TN); Ranitidine (USAN/INN); Ranitidine [USAN:BAN:INN]; N-(2-((5-((Dimethylamino)methyl)furfuryl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; (E)-1-N'-[2-[[5-(dimethylaminomethyl)furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({5-[(dimethylamino)methyl]-2-furyl}methyl)sulfanyl]ethyl}-N'-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({5-[(dimethylamino)methyl]furan-2-yl}methyl)sulfanyl]ethyl}-N'-methyl-2-nitroethene-1,1-diamine Click to Show/Hide
Disease Class	DA61: Peptic ulcer
Therapeutic Class	Antiulcer Agents
Structure
Structure	3D Structure		2D Structure
Formula	C13H22N4O3S
InChI	1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3/b13-9+
InChIKey	VMXUWOKSQNHOCA-UKTHLTGXSA-N
Canonical SMILES	CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C
External Link
	Pubchem ID	3001055
	CAS Number	82530-72-1
	CHEBI ID	8776
	TTD ID	D0B8WN
	INTEDE ID	DR1393
	VARIDT ID	DR00163

Drug-Drug Interaction Network
Sunburst Graph		Legend Information AM001 Affected gastrointestinal absorption AM002 Affected cellular transport AM004 Affected intra/extra-hepatic metabolism AM005 Affected excretion pathways AM006 Pharmacodynamic additive effects AM007 Pharmacodynamic antagonistic effects BM001 Altered gastrointestinal dynamics BM005 Altered gastric pH BM010 Transporter inhibition BM011 Transporter induction BM017 CYP450 enzyme inhibition BM022 CYP450 enzyme induction BM028 Competitive inhibition of renal tubular secretion BM049 Increased risk of atrioventricular block BM051 Increased risk of bradycardia BM055 Increased risk of hepatotoxicity BM075 Increased risk of photosensitivity reactions BM081 Increased risk of ventricular arrhythmias BM091 Antagonize the effect of cholinergic agents BM095 Antagonize the effect of neuromuscular blocking agents
Relation Graph

Full list of drugs interacting with Ranitidine
Affected gastrointestinal absorption
	Altered gastrointestinal dynamics					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0342		Cisapride	C23H29ClFN3O4	6917698	Minor		Inter Info	[143]
	Altered gastric pH					Drug Num: 51
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0116		Atazanavir	C38H52N6O7	148192	Major		Inter Info	[7], [8], [9], [10], [11], [12], [13], [14]
D0428		Dasatinib	C22H26ClN7O2S	3062316	Major		Inter Info	[15]
D1124		Neratinib	C30H29ClN6O3	9915743	Major		Inter Info	[18], [19]
D1232		Pazopanib	C21H23N7O2S	10113978	Major		Inter Info	[7], [20], [21], [22], [23], [24]
D1404		Rilpivirine	C22H18N6	6451164	Major		Inter Info	[25]
D1459		Selpercatinib	C29H31N7O3	134436906	Major		Inter Info	[7], [26]
D0013		Acetohexamide	C15H20N2O4S	1989	Moderate		Inter Info	[28], [29], [30], [31]
D0325		Chlorpropamide	C10H13ClN2O3S	2727	Moderate		Inter Info	[28], [29], [30], [31]
D0439		Delavirdine	C22H28N6O3S	5625	Moderate		Inter Info	[32]
D0595		Erlotinib	C22H23N3O4	176870	Moderate		Inter Info	[18], [7], [40], [41]
D0713		Gefitinib	C22H24ClFN4O3	123631	Moderate		Inter Info	[42]
D0727		Glimepiride	C24H34N4O5S	3476	Moderate		Inter Info	[28], [29], [30], [31]
D0008		Acalabrutinib	C26H23N7O2	71226662	Moderate		Inter Info	[47]
D0141		Bacampicillin	C21H27N3O7S	441397	Moderate		Inter Info	[77], [78]
D0195		Bosutinib	C26H29Cl2N5O3	5328940	Moderate		Inter Info	[7], [79]
D0278		Cefditoren	C19H18N6O5S3	9870843	Moderate		Inter Info	[81]
D0288		Cefpodoxime	C15H17N5O6S2	6335986	Moderate		Inter Info	[77], [82], [83], [78]
D0297		Cefuroxime	C16H16N4O8S	5479529	Moderate		Inter Info	[77], [82], [83], [78]
D0302		Ceritinib	C28H36ClN5O3S	57379345	Moderate		Inter Info	[84]
D0406		Dabrafenib	C23H20F3N5O2S2	44462760	Moderate		Inter Info	[18], [7], [85], [86], [87], [88], [43]
D0409		Dacomitinib	C24H25ClFN5O2	11511120	Moderate		Inter Info	[7], [89]
D0692		Fosamprenavir	C25H36N3O9PS	131536	Moderate		Inter Info	[94]
D0728		Glipizide	C21H27N5O4S	3478	Moderate		Inter Info	[28], [29], [30], [31]
D0730		Glyburide	C23H28ClN3O5S	3488	Moderate		Inter Info	[28], [29], [30], [31]
D0867		Itraconazole	C35H38Cl2N8O4	55283	Moderate		Inter Info	[95], [96], [97], [98]
D0880		Ketoconazole	C26H28Cl2N4O4	456201	Moderate		Inter Info	[100], [95], [101], [102], [103], [7], [104], [105], [106], [107]
D0894		Lapatinib	C29H26ClFN4O4S	208908	Moderate		Inter Info	[7], [108]
D0898		Ledipasvir	C49H54F2N8O6	67505836	Moderate		Inter Info	[110]
D1136		Nilotinib	C28H22F3N7O	644241	Moderate		Inter Info	[18], [7], [115]
D1258		Pexidartinib	C20H15ClF3N5	25151352	Moderate		Inter Info	[117]
D1315		Posaconazole	C37H42F2N8O4	468595	Moderate		Inter Info	[118], [119], [120], [121], [122], [123], [124], [125], [126], [127], [128]
D1603		Tolbutamide	C12H18N2O3S	5505	Moderate		Inter Info	[28], [29], [30], [31]
D1686		Velpatasvir	C49H54N8O8	67683363	Moderate		Inter Info	[138]
D1601		Tolazamide	C14H21N3O3S	5503	Moderate		Inter Info	[28], [29], [30], [31]
D0395		Cyanocobalamin	C63H88CoN14O14P	5311498	Minor		Inter Info	[147], [148], [149], [150], [151]
D0539		Duloxetine	C18H19NOS	60835	Minor		Inter Info	[152]
D0573		Enoxacin	C15H17FN4O3	3229	Minor		Inter Info	[153], [154]
D0049		Aluminum hydroxide	AlH3O3	10176082	Minor		Inter Info	[156], [157], [49], [158], [159], [160], [161], [162], [163], [164], [165], [166]
D0133		Axitinib	C22H18N4OS	6450551	Minor		Inter Info	[167]
D0236		Calcium carbonate	CCaO3	10112	Minor		Inter Info	[156], [157], [49], [158], [159], [160], [161], [162], [163], [164], [165], [166]
D0483		Didanosine	C10H12N4O3	135398739	Minor		Inter Info	[168], [169]
D0967		Magaldrate	AlHMgO5S+2	3086011	Minor		Inter Info	[156], [157], [49], [158], [159], [160], [161], [162], [163], [164], [165], [166]
D0968		Magnesium carbonate	CMgO3	11029	Minor		Inter Info	[156], [157], [49], [158], [159], [160], [161], [162], [163], [164], [165], [166]
D0973		Magnesium hydroxide	H2MgO2	14791	Minor		Inter Info	[156], [157], [49], [158], [159], [160], [161], [162], [163], [164], [165], [166]
D0974		Magnesium oxide	MgO	14792	Minor		Inter Info	[156], [157], [49], [158], [159], [160], [161], [162], [163], [164], [165], [166]
D0989		Mecobalamin	C63H91CoN13O14P	10898559	Minor		Inter Info	[148], [149], [151]
D1313		Ponatinib	C29H27F3N6O	24826799	Minor		Inter Info	[18], [174]
D1328		Prasugrel	C20H20FNO3S	6918456	Minor		Inter Info	[175], [176]
D1377		Raltegravir	C20H21FN6O5	54671008	Minor		Inter Info	[177]
D1681		Vandetanib	C22H24BrFN4O2	3081361	Minor		Inter Info	[18], [7], [20], [178]
D1701		Vismodegib	C19H14Cl2N2O3S	24776445	Minor		Inter Info	[18], [7], [179]
Affected cellular transport
	Transporter induction					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0958		Lumacaftor	C24H18F2N2O5	16678941	Moderate		Inter Info	[7], [113], [114]
Affected intra/extra-hepatic metabolism
	CYP450 enzyme inhibition					Drug Num: 10
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0947		Loperamide	C29H33ClN2O2	3955	Major		Inter Info	[1], [2], [3], [4], [5], [6]
D0901		Lemborexant	C22H20F2N4O2	56944144	Major		Inter Info	[16], [17]
D0064		Aminophylline	C16H24N10O4	9433	Moderate		Inter Info	[48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63], [64], [65], [66], [67], [68], [69], [70], [71], [72], [73], [74], [75], [76]
D0559		Eliglustat	C23H36N2O4	23652731	Moderate		Inter Info	[90]
D0665		Flibanserin	C20H21F3N4O	6918248	Moderate		Inter Info	[93]
D0944		Lomitapide	C39H37F6N3O2	9853053	Moderate		Inter Info	[111], [112]
D1201		Oxtriphylline	C12H21N5O3	656652	Moderate		Inter Info	[48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63], [64], [65], [66], [67], [68], [69], [70], [71], [72], [73], [74], [75], [76]
D1371		Quinidine	C20H24N2O2	441074	Moderate		Inter Info	[133], [134], [135], [136]
D1570		Theophylline	C7H8N4O2	2153	Moderate		Inter Info	[48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63], [64], [65], [66], [67], [68], [69], [70], [71], [72], [73], [74], [75], [76]
D1134		Nifedipine	C17H18N2O6	4485	Minor		Inter Info	[173], [43]
	CYP450 enzyme induction					Drug Num: 2
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1060		Midazolam	C18H13ClFN3	4192	Moderate		Inter Info	[43]
D1632		Triazolam	C17H12Cl2N4	5556	Moderate		Inter Info	[43]
Affected excretion pathways
	Competitive inhibition of renal tubular secretion					Drug Num: 6
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0576		Entecavir	C12H15N5O3	135398508	Moderate		Inter Info	[39]
D1241		Pemetrexed	C20H21N5O6	135410875	Moderate		Inter Info	[44]
D1343		Procainamide	C13H21N3O	4913	Moderate		Inter Info	[129], [130], [131], [132]
D1656		Trospium	C25H30NO3+	5284632	Moderate		Inter Info	[7], [139], [140]
D1061		Midodrine	C12H18N2O4	4195	Minor		Inter Info	[155]
D0998		Memantine	C12H21N	4054	Minor		Inter Info	[170], [171], [172]
Pharmacodynamic additive effects
	Increased risk of bradycardia					Drug Num: 6
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1474		Siponimod	C29H35F3N2O3	44599207	Major		Inter Info	[18], [27]
D0204		Brigatinib	C29H39ClN7O2P	68165256	Moderate		Inter Info	[80]
D0661		Fingolimod	C19H33NO2	107970	Moderate		Inter Info	[91], [92]
D0868		Ivabradine	C27H36N2O5	132999	Moderate		Inter Info	[18], [99]
D0897		Lasmiditan	C19H18F3N3O2	11610526	Moderate		Inter Info	[109]
D1211		Ozanimod	C23H24N4O3	52938427	Moderate		Inter Info	[116]
	Increased risk of hepatotoxicity					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0011		Acetaminophen	C8H9NO2	1983	Minor		Inter Info	[141], [142]
	Increased risk of photosensitivity reactions					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1314		Porfimer sodium	C68H74N8O11	135577896	Moderate		Inter Info	[45], [7], [46]
	Increased risk of ventricular arrhythmias					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1569		Thalidomide	C13H10N2O4	5426	Moderate		Inter Info	[18], [7], [137]
Pharmacodynamic antagonistic effects
	Antagonize the effect of cholinergic agents					Drug Num: 5
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0516		Donepezil	C24H29NO3	3152	Moderate		Inter Info	[33], [34], [35], [36], [37], [38]
D0707		Galantamine	C17H21NO3	9651	Moderate		Inter Info	[33], [34], [35], [36], [37], [38]
D1285		Physostigmine	C15H21N3O2	5983	Moderate		Inter Info	[33], [34], [35], [36], [37], [38]
D1418		Rivastigmine	C14H22N2O2	77991	Moderate		Inter Info	[33], [34], [35], [36], [37], [38]
D1525		Tacrine	C13H14N2	1935	Moderate		Inter Info	[33], [34], [35], [36], [37], [38]
	Antagonize the effect of neuromuscular blocking agents					Drug Num: 12
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0343		Cisatracurium	C53H72N2O12+2	62887	Minor		Inter Info	[144], [145], [146]
D0122		Atracurium	C53H72N2O12+2	47319	Minor		Inter Info	[144], [145], [146]
D0522		Doxacurium	C56H78N2O16+2	60169	Minor		Inter Info	[144], [145], [146]
D1047		Metocurine	C40H48N2O6+2	21233	Minor		Inter Info	[144], [145], [146]
D1080		Mivacurium	C58H80N2O14+2	5281042	Minor		Inter Info	[144], [145], [146]
D1219		Pancuronium	C35H60N2O4+2	441289	Minor		Inter Info	[144], [145], [146]
D1295		Pipecuronium	C35H62N4O4+2	50192	Minor		Inter Info	[144], [145], [146]
D1384		Rapacuronium	C37H61N2O4+	5311399	Minor		Inter Info	[144], [145], [146]
D1659		Tubocurarine	C37H41N2O6+	6000	Minor		Inter Info	[144], [145], [146]
D1684		Vecuronium	C34H57N2O4+	39765	Minor		Inter Info	[144], [145], [146]
D1420		Rocuronium	C32H53N2O4+	441290	Minor		Inter Info	[144], [145], [146]
D1510		Succinylcholine	C14H30N2O4+2	5314	Minor		Inter Info	[144], [145], [146]

References
1	Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
2	Kim KA, Chung J, Jung DH, Park JY "Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes." Eur J Clin Pharmacol 60 (2004): 575-81. [PMID: 15365656]
3	Niemi M, Tornio A, Pasanen MK, Fredrikson H, Neuvonen PJ, Backman JT "Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide." Eur J Clin Pharmacol 62 (2006): 463-72. [PMID: 16758263]
4	Product Information. Imodium (loperamide). Janssen Pharmaceutica, Titusville, NJ.
5	Tayrouz Y, Ganssmann B, Ding R, et al. "Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement." Clin Pharmacol Ther 70 (2001): 405-14. [PMID: 11719726]
6	US Food and Drug Administration "FDA warns about serious heart problems with high doses of the antidiarrheal medicine loperamide (Imodium), including from abuse and misuse.".
7	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
8	Drug interactions. Atazanavir and acid-reducing agents. TreatmentUpdate 18 (2006): 4. [PMID: 17209238]
9	Klein CE, Chiu YL, Cai Y, et al. "Effects of Acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir." J Clin Pharmacol 48 (2008): 553-62. [PMID: 18440920]
10	Product Information. Evotaz (atazanavir-cobicistat). Bristol-Myers Squibb, Princeton, NJ.
11	Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
12	Ray JE, Marriott D, Bloch MT, McLachlan AJ "Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic." Br J Clin Pharmacol 60 (2005): 291-9. [PMID: 16120068]
13	Agarwala S, Persson A, Eley T, et al "Effect of famotidine 20 and 40 mg dosing regimens on the bioavailability of atazanavir with ritonavir in combination with tenofovir in healthy subjects".
14	Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, DelGiudice P, Montagne N, Schapiro JM, Dellamonica P "Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study." Aids 14 (2000): 1333-9. [PMID: 10930147]
15	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
16	Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
17	Product Information. Dayvigo (lemborexant). Eisai Inc, Woodcliff Lake, NJ.
18	Cerner Multum, Inc. "Australian Product Information.".
19	Product Information. Nerlynx (neratinib). Puma Biotechnology, Inc., Los Angeles, CA.
20	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
21	Product Information. Votrient (pazopanib). GlaxoSmithKline, Research Triangle Park, NC.
22	Tan AR, Gibbon DG, Stein MN, et al. "Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors." Cancer Chemother Pharmacol 71 (2013): 1635-43. [PMID: 23636448]
23	van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG "Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective." Lancet Oncol 15 (2014): e315-e326. [PMID: 24988935]
24	Yu G, Zheng QS, Wang DX, Zhou HH, Li GF "Drug interactions between tyrosine-kinase inhibitors and acid suppressive agents: more than meets the eye." Lancet Oncol 15 (2014): e469-70. [PMID: 25281461]
25	Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
26	Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
27	Product Information. Mayzent (siponimod). Novartis Pharmaceuticals, East Hanover, NJ.
28	Dey NG, Castleden CM, Ward J, et al "The effect of cimetidine on tolbutamide kinetics." Br J Clin Pharmacol 16 (1983): 438-40. [PMID: 6626438]
29	Feely J, Collins WCJ, Cullen CM, et al. "Potentiation of the hypoglycaemic response to glipizide in diabetic patients by histamine H2-receptor antagonists." Br J Clin Pharmacol 35 (1993): 321-3. [PMID: 8471413]
30	Kubacka RT, Antal EJ, Juhl RP "The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics." Br J Clin Pharmacol 23 (1987): 743-51. [PMID: 3111514]
31	Lee K, Mize R, Lowenstein SR "Glyburide-induced hypoglycemia and ranitidine." Ann Intern Med 107 (1987): 261-2. [PMID: 3111324]
32	Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI.
33	Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
34	Carnahan RM, Lund BC, Perry PJ, Chrischilles EA "The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice?" J Am Geriatr Soc 52 (2004): 2082-7. [PMID: 15571547]
35	Edwards KR, O'Connor JT "Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors." J Am Geriatr Soc 50 (2002): 1165-6. [PMID: 12110086]
36	Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH "Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts." Arch Intern Med 163 (2003): 2716-2724. [PMID: 14662625]
37	Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K "Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride." J Am Geriatr Soc 46 (1998): 8-13. [PMID: 9434659]
38	Roe CM, Anderson MJ, Spivack B "Use of anticholinergic medications by older adults with dementia." J Am Geriatr Soc 50 (2002): 836-42. [PMID: 12028169]
39	Product Information. Baraclude (entecavir). Bristol-Myers Squibb, Princeton, NJ.
40	Duong S, Leung M "Should the concomitant use of erlotinib and acid-reducing agents be avoided? The drug interaction between erlotinib and acid-reducing agents." J Oncol Pharm Pract 17 (2011): 448-52. [PMID: 20716581]
41	Product Information. Tarceva (erlotinib). Genentech, South San Francisco, CA.
42	Product Information. Iressa (gefitinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
43	Product Information. Zantac (ranitidine). Glaxo Wellcome, Research Triangle Park, NC.
44	Product Information. Alimta (pemetrexed). Lilly, Eli and Company, Indianapolis, IN.
45	Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
46	Product Information. Photofrin (porfimer). Sanofi Winthrop Pharmaceuticals, New York, NY.
47	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
48	Anderson JR, Poklis A, Slavin RG "A fatal case of theophylline intoxication." Arch Intern Med 143 (1983): 559-60. [PMID: 6830388]
49	Bachmann KA, Sullivan TJ, Jauregui L, Reese J, Miller K, Levine L "Drug interactions of h-2-receptor antagonists." Scand J Gastroenterol 29 (1994): 14-9. [PMID: 7863246]
50	Bauman JH, Kimelblatt BJ, Caraccio TR, Silverman HM, Simon GI, Beck GJ "Cimetidine-theophylline interaction: report of four patients." Ann Allergy 48 (1982): 100-2. [PMID: 6121526]
51	Boehning W "Effect of cimetidine and ranitidine on plasma theophylline in patients with chronic obstructive airways disease treated with theophylline and corticosteroids." Eur J Clin Pharmacol 38 (1990): 43-5. [PMID: 2328746]
52	Campbell MA, Plachetka JR, Jackson JE, Moon JF, Finley PR "Cimetidine decreases theophylline clearance." Ann Intern Med 95 (1981): 68-9. [PMID: 7247131]
53	Dal Negro R, Pomari C, Turco P "Famotidine and theophylline pharmacokinetics. An unexpected cimetidine-like interaction in patients with chronic obstructive pulmonary disease." Clin Pharmacokinet 24 (1993): 255-8. [PMID: 8462230]
54	Fenje PC, Isles AF, Baltodano A, MacLeod SM, Soldin S "Interaction of cimetidine and theophylline in two infants." Can Med Assoc J 126 (1982): 1178. [PMID: 7074441]
55	Fernandes E, Melewicz FM "Ranitidine and theophylline." Ann Intern Med 100 (1984): 459. [PMID: 6320702]
56	Hardman JG, Gilman AG, Limbird LE eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed." New York, NY: McGraw-Hill (1995):.
57	Hegman GW, Gilbert RP "Ranitidine-theophylline interaction--fact or fiction?" Ann Pharmacother 25 (1991): 21-5. [PMID: 2008782]
58	Hsu K, Garton A, Sproule BJ, Tam YK, Leggatt D, Herbert FA "The influence of orally administered cimetidine and theophylline on the elimination of each drug in patients with chronic airways obstruction." Am Rev Respir Dis 130 (1984): 740-3. [PMID: 6497156]
59	Jackson JE, Powell JR, Wandell M, Bentley J, Dorr R "Cimetidine decreases theophylline clearance." Am Rev Respir Dis 123 (1981): 615-7. [PMID: 7023306]
60	Kehoe WA, Sands CD, Long LF, et al "Effect of ranitidine on theophylline metabolism in healthy Koreans living in China." Ann Pharmacother 30 (1996): 133-7. [PMID: 8835044]
61	Kelly HW "Lack of evidence for reduction of theophylline clearance by ranitidine." Am J Med 86 (1989): 629-32. [PMID: 2712078]
62	Kelly HW, Powell JR, Donohue JF "Ranitidine at very large doses does not inhibit theophylline elimination." Clin Pharmacol Ther 39 (1986): 577-81. [PMID: 3698466]
63	Lin JH, Chremos AN, Chiou R, Yeh KC, Williams R "Comparative effect of famotidine and cimetidine on the pharmacokinetics of theophylline in normal volunteers." Br J Clin Pharmacol 24 (1987): 669-72. [PMID: 2893637]
64	Lofgren RP, Gilbertson RA "Cimetidine and theophylline." Ann Intern Med 96 (1982): 378. [PMID: 6800293]
65	Loi CM, Parker BM, Cusack BJ, Vestal RE "Aging and drug interactions .3. individual and combined effects of cimetidine and ciprofloxacin on theophylline metabolism in healthy male and female nonsmokers." J Pharmacol Exp Ther 280 (1997): 627-37. [PMID: 9023273]
66	Ohashi K, Sakamoto K, Sudo T, Tateishi T, Fujimura A, Shiga T, Ebihara A "Effects of diltiazem and cimetidine on theophylline oxidative metabolism." J Clin Pharmacol 33 (1993): 1233-7. [PMID: 8126258]
67	Powell JR, Rogers JF, Wargin WA, Cross RE, Eshelman FN "Inhibition of theophylline clearance by cimetidine but not ranitidine." Arch Intern Med 144 (1984): 484-6. [PMID: 6322709]
68	Pride M, Deamer RL "Over-the-counter cimetidine and theophylline interaction." Am Fam Physician 52 (1995): 2180. [PMID: 7484712]
69	Reitberg DP, Bernhard H, Schentag JJ "Alteration of theophylline clearance and half-life by cimetidine in normal volunteers." Ann Intern Med 95 (1981): 582-5. [PMID: 7294546]
70	Roy AK, Cuda MP, Levine RA "Induction of theophylline toxicity and inhibition of clearance rates by ranitidine." Am J Med 85 (1988): 525-7. [PMID: 3177399]
71	Schwartz JI, Bachmann KA, Bond LW, Mahajan VK "Impact of cimetidine on the pharmacokinetics of the theophylline." Clin Pharm 1 (1982): 534-8. [PMID: 7185539]
72	Skinner MH, Lenert L, Blaschke TF "Theophylline toxicity subsequent to ranitidine administration: a possible drug-drug interaction." Am J Med 86 (1989): 129-32. [PMID: 2910084]
73	Upton RA "Pharmacokinetic interactions between theophylline and other medication (Part II)." Clin Pharmacokinet 20 (1991): 135-50. [PMID: 1709398]
74	Verdiani P, Di Carlo S, Baronti A "Famotidine effects on theophylline pharmacokinetics in subjects affected by COPD: comparison with cimetidine and placebo." Chest 94 (1988): 807-10. [PMID: 3168576]
75	Weinberger MM, Smith G, Milavetz G, Hendeles L "Decreased clearance of theophylline due to cimetidine ." N Engl J Med 304 (1981): 672. [PMID: 7453751]
76	Bachmann K, Sullivan TJ, Reese JH, Jauregui L, Miller K, Scott M, Yeh KC, Stepanavage M, King JD, Schwartz J "Controlled study of the putative interaction between famotidine and theophylline in patients with chronic obstructive pulmonary disease." J Clin Pharmacol 35 (1995): 529-35. [PMID: 7657856]
77	Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71. [PMID: 9784931]
78	Sommers DK, van Wyk M, Moncrieff J, Schoeman HS "Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil." Br J Clin Pharmacol 18 (1984): 535-9. [PMID: 6091711]
79	Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
80	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
81	Product Information. Spectracef (cefditoren). TAP Pharmaceuticals Inc, Deerfield, IL.
82	Hughes GS, Heald DL, Barker KB, et al. "The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil." Clin Pharmacol Ther 46 (1989): 674-85. [PMID: 2557183]
83	Saathoff N, Lode H, Neider K, et al "Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist." Antimicrob Agents Chemother 36 (1992): 796-800. [PMID: 1354432]
84	Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
85	Product Information. Aciphex (rabeprazole) Janssen Pharmaceuticals, Titusville, NJ.
86	Product Information. Dexilant (dexlansoprazole). Takeda Pharmaceuticals America, Lincolnshire, IL.
87	Product Information. Prevacid (lansoprazole). TAP Pharmaceuticals Inc, Deerfield, IL.
88	Product Information. Tafinlar (dabrafenib). GlaxoSmithKline, Research Triangle Park, NC.
89	Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
90	Product Information. Cerdelga (eliglustat). Genzyme Corporation, Cambridge, MA.
91	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
92	FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod).".
93	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
94	Product Information. Lexiva (fosamprenavir). GlaxoSmithKline, Research Triangle Park, NC.
95	Blum RA, D'Andrea DT, Florentino BM, et al "Increased gastric pH and the bioavailability of fluconazole and ketoconazole." Ann Intern Med 114 (1991): 755-7. [PMID: 2012358]
96	Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32. [PMID: 10730911]
97	Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33. [PMID: 2330488]
98	Product Information. Sporonox (itraconazole). Janssen Pharmaceutica, Titusville, NJ.
99	Product Information. Corlanor (ivabradine). Amgen USA, Thousand Oaks, CA.
100	Adachi M, Hinatsu Y, et.al "Improved dissolution and absorption of ketoconazole in the presence of organic acids as pH-modifiers." Eur J Pharm Sci 76 (2015): 225-30. [PMID: 25988287]
101	Carlson JA, Mann HJ, Canafax DM "Effect of pH on disintegration and dissolution of ketoconazole tablets." Am J Hosp Pharm 40 (1983): 1334-6. [PMID: 6310994]
102	Cerner Multum, Inc "ANVISA Bulario Eletrnico.".
103	Cerner Multum, Inc. "Canadian Product Information.".
104	Chin TWF, Loeb M, Fong IW "Effects of an acidic beverage (coca-cola) on absorption of ketoconazole." Antimicrob Agents Chemother 39 (1995): 1671-5. [PMID: 7486898]
105	Piscitelli SC, Goss TF, Wilton JH, D'Andrea DT, Goldstein H, Schentag JJ "Effects of ranitidine and sucralfate on ketoconazole bioavailability." Antimicrob Agents Chemother 35 (1991): 1765-71. [PMID: 1952845]
106	Product Information. Ketoconazole (ketoconazole). Mylan Pharmaceuticals Inc, Morgantown, WV.
107	Van der Meer JW, Keuning JJ "The influence of gastric acidity on the bio-availability of ketoconazole." J Antimicrob Chemother 6 (1980): 552-4. [PMID: 6253434]
108	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
109	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
110	Product Information. Harvoni (ledipasvir-sofosbuvir). Gilead Sciences, Foster City, CA.
111	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
112	Product Information. Qelbree (viloxazine). Supernus Pharmaceuticals Inc, Rockville, MD.
113	Product Information. Orkambi (ivacaftor-lumacaftor). Vertex Pharmaceuticals, Cambridge, MA.
114	Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor). Vertex Pharmaceuticals, Cambridge, MA.
115	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
116	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
117	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
118	Alffenaar JW, van Assen S, van der Werf TS, Kosterink JG, Uges DR "Omeprazole significantly reduces posaconazole serum trough level." Clin Infect Dis 48 (2009): 839. [PMID: 19220151]
119	Canadian Pharmacists Association.
120	Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJ "Multicenter study of posaconazole therapeutic drug monitoring: exposure-response and factors affecting concentration." Antimicrob Agents Chemother 56 (2012): 5503-10. [PMID: 22890761]
121	Krishna G, Abutarif M, Xuan F, Martinho M, Angulo D, Cornely OA "Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome." Pharmacotherapy 28 (2008): 1223-32. [PMID: 18823218]
122	Krishna G, Moton A, Ma L, Medlock MM, McLeod J "The pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers." Antimicrob Agents Chemother 53 (2009): 958-66. [PMID: 19075045]
123	Neubauer WC, Engelhardt M, Konig A, et al. "Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method." Antimicrob Agents Chemother 54 (2010): 4029-32. [PMID: 20547790]
124	Product Information. Noxafil (posaconazole). Schering-Plough Corporation, Kenilworth, NJ.
125	Shields RK, Clancy CJ, Vadnerkar A, et al "Posaconzaole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy." Antimicrob Agents Chemother 55 (2011): 1308-11. [PMID: 21189337]
126	Vaes M, Hites M, Cotton F, et al. "Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplasic syndrome." Antimicrob Agents Chemother 56 (2012): 6298-303. [PMID: 23027198]
127	Walravens J, Brouwers J, Spriet I, Tack J, Annaert P, Augustijns P "Effect of pH and Comedication on Gastrointestinal Absorption of Posaconazole: Monitoring of Intraluminal and Plasma Drug Concentrations." Clin Pharmacokinet 50 (2011): 725-34. [PMID: 21973269]
128	Krishna G, Moton A, Ma L, Malavade D, Medlock M, McLeod J "Effect of gastric pH, dosing regimen and prandial state, food and meal timing relative to dose, and gastro-intestinal motility on absorption and pharmacokinetics of the antifungal posaconazole." 18th European Congress of Clinical Microbiology and Infectious Diseases April (2008): 20.
129	Martin BK "Effect of ranitidine on procainamide disposition." Br J Clin Pharmacol 19 (1985): 858-60. [PMID: 4027133]
130	Rocci ML, Kosoglou T, Ferguson RK, Vlasses PH "Ranitidine-induced changes in the renal and hepatic clearances of procainamide are correlated." J Pharmacol Exp Ther 248 (1989): 923-8. [PMID: 2467982]
131	Rodvold KA, Paloucek FP, Jung D, Gallastegui J "Interaction of steady-state procainamide with H2-receptor antagonists cimetidine and ranitidine." Ther Drug Monit 9 (1987): 378-83. [PMID: 2447687]
132	Somogyi A, Bochner F "Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man." Br J Clin Pharmacol 18 (1984): 175-81. [PMID: 6091709]
133	Farringer JA, McWay-Hess K, Clementi WA "Cimetidine-quinidine interaction." Clin Pharm 3 (1984): 81-3. [PMID: 6697678]
134	Hardy BG, Istvan ZT, Golden L, Lalka D, Schentag JJ "Effect of cimetidine on the pharmacokinetics pharmacodynamics of quinidine." Am J Cardiol 52 (1983): 172-5. [PMID: 6858908]
135	Iliopoulou A, Kontogiannis D, Tsoutsos D, Moulopoulos S "Quinidine-ranitidine adverse reaction." Eur Heart J 7 (1986): 360. [PMID: 3720764]
136	Kolb KW, Garnett WR, Small RE, Vetrovec GW, Kline BJ, Fox T "Effect of cimetidine on quinidine clearance." Ther Drug Monit 6 (1984): 306-12. [PMID: 6506138]
137	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
138	Product Information. Epclusa (sofosbuvir-velpatasvir). Gilead Sciences, Foster City, CA.
139	Canadian Pharmacists Association "e-CPS."
140	Product Information. Sanctura (trospium chloride). Odyssey Pharmaceutical, East Hanover, NJ.
141	Jack D, Thomas M, Skidmore IF "Ranitidine and paracetamol metabolism." Lancet 2 (1985): 1067. [PMID: 2865542]
142	Rogers SA, Gale KC, Newton JF, et al "Inhibition by ranitidine of acetaminophen conjugation and its possible role in ranitidine potentiation of acetaminophen-induced hepatotoxicity." J Pharmacol Exp Ther 245 (1988): 887-94. [PMID: 3133464]
143	Rowbotham DJ, Milligan K, McHugh P "Effect of single doses of cisapride and ranitidine administered simultaneously on plasma concentrations of cisapride and ranitidine." Br J Anaesth 67 (1991): 302-5. [PMID: 1911017]
144	Katende RS, Dimich I "Resistance to nondepolarizing muscle relaxants in a patient treated with ranitidine." Mt Sinai J Med 54 (1987): 330-1. [PMID: 2955219]
145	McCarthy G, Mirakhur RK, Elliott P, Wright J "Effect of H2-receptor antagonist pretreatment on vecuronium- and atracurium-induced neuromuscular block." Br J Anaesth 66 (1991): 713-5. [PMID: 1676594]
146	Woodworth GE, Sears DH, Grove TM, et al "The effect of cimetidine and ranitidine on the duration of action of succinylcholine." Anesth Analg 68 (1989): 295-7. [PMID: 2919769]
147	Bradford GS, Taylor CT "Omeprazole and vitamin B-12 deficiency." Ann Pharmacother 33 (1999): 641-3. [PMID: 10369631]
148	Dutta SK "Vitamin b-12 malabsorption and omeprazole therapy." J Am Coll Nutr 13 (1994): 544-5. [PMID: 7706583]
149	Lavy NW "Omeprazole and vitamin B12." Ann Intern Med 121 (1994): 74. [PMID: 8198354]
150	Marcuard SP, Albernaz L, Khazanie PG "Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin-b12)." Ann Intern Med 120 (1994): 211-5. [PMID: 8273984]
151	Salom IL, Silvis SE, Doscherholmen A "Effect of cimetidine on the absorption of vitamin B12." Scand J Gastroenterol 17 (1982): 129-31. [PMID: 7134827]
152	Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
153	Lebsack ME, Nix D, Ryerson B, et al "Effect of gastric acidity on enoxacin absorption." Clin Pharmacol Ther 52 (1992): 252-6. [PMID: 1526081]
154	Misiak PM, Eldon MA, Toothaker RD, Sedman AJ "Effects of oral cimetidine or ranitidine on the pharmacokinetics of intravenous enoxacin." J Clin Pharmacol 33 (1993): 53-6. [PMID: 8429114]
155	Product Information. ProAmatine (midodrine). Roberts Pharmaceutical Corporation, Eatontown, NJ.
156	Albin H, Vincon G, Begaud B, Bistue C, Perez P "Effect of aluminum phosphate on the bioavailability of ranitidine." Eur J Clin Pharmacol 32 (1987): 97-9. [PMID: 3582475]
157	Albin H, Vincon G, Demotes-Mainard F, et al "Effect of aluminium phosphate on the bioavailability of cimetidine and prednisolone." Eur J Clin Pharmacol 26 (1984): 271-3. [PMID: 6723769]
158	Barzaghi N, Gatti G, Crema F, Perucca E "Impaired bioavailability of famotidine given concurrently with a potent antacid." J Clin Pharmacol 29 (1989): 670-2. [PMID: 2569486]
159	Bodemar G, Norlander B, Walan A "Diminished absorption of cimetidine caused by antacids." Lancet 02/24/79 (1979): 444-5. [PMID: 84296]
160	Covington TR, Lawson LC, Young LL, eds. "Handbook of Nonprescription Drugs. 10th ed." Washington, DC: American Pharmaceutical Association (1993):.
161	Donn KH, Eshelman FN, Plachetka JR, et al "The effects of antacid and propantheline on the absorption of oral ranitidine." Pharmacotherapy 4 (1984): 89-92. [PMID: 6326064]
162	Lin JH, Chremos AN, Kanovsky SM, Schwartz S, Yeh KC, Kann J "Effects of antacids and food on absorption of famotidine." Br J Clin Pharmacol 24 (1987): 551-3. [PMID: 2891370]
163	Mihaly GW, Marino AT, Webster LK, Jones DB, Louis WJ, Smallwood RA "High dose of antacid (Mylanta II) reduces bioavailability of ranitidine." Br Med J 285 (1982): 998-9. [PMID: 6289961]
164	Russell WL, Lopez LM, Normann SA, et al "Effect of antacids on predicted steady-state cimetidine concentrations." Dig Dis Sci 29 (1984): 385-9. [PMID: 6714054]
165	Shelly DW, Doering PL, Russell WL, Guild RT, Lopez LM, Perrin J "Effect of concomitant antacid administration on plasma cimetidine concentrations during repetitive dosing." Drug Intell Clin Pharm 20 (1986): 792-5. [PMID: 3769772]
166	Steinberg WM, Lewis JH, Katz DM "Antacids inhibit absorption of cimetidine." N Engl J Med 307 (1982): 400-4. [PMID: 7088113]
167	Product Information. Inlyta (axitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
168	Knupp CA, Graziano FM, Dixon RM, Barbhaiya RH "Pharmacokinetic-interaction study of didanosine and ranitidine in patients seropositive for human immunodeficiency virus." Antimicrob Agents Chemother 36 (1992): 2075-9. [PMID: 1444287]
169	Product Information. Videx (didanosine). Bristol-Myers Squibb, Princeton, NJ.
170	Ace LN, Jaffe JM, Kunka RL "Effect of food and an antacid on quinidine bioavailability." Biopharm Drug Dispos 4 (1983): 183-90. [PMID: 6882885]
171	Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76. [PMID: 8739026]
172	Product Information. Namenda (memantine). Forest Pharmaceuticals, St. Louis, MO.
173	Product Information. Tagamet (cimetidine). SmithKline Beecham, Philadelphia, PA.
174	Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
175	Product Information. Effient (prasugrel). Lilly, Eli and Company, Indianapolis, IN.
176	Small DS, Farid NA, Payne CD, et al. "Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel." J Clin Pharmacol 48 (2008): 475-84. [PMID: 18303127]
177	Product Information. Isentress (raltegravir). Merck & Company Inc, West Point, PA.
178	Product Information. Vandetanib (vandetanib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
179	Product Information. Erivedge (vismodegib). Genentech, South San Francisco, CA.

Details of Drug

Details of Drug

Cite MecDDI

About MecDDI

Correspondence